Publications by authors named "Nobuatsu Aoki"
Article Synopsis
- There is limited evidence on schizophrenia relapse following electroconvulsive therapy (ECT), prompting a systematic review to gather more data on this issue.
- The study analyzed 29 research papers, finding that relapse rates for schizophrenia after acute ECT were 24% at 3 months, increasing to 55% by 24 months.
- Adding maintenance ECT along with antipsychotics significantly lowered the relapse rate to 20% at the 6-month mark, indicating the need for further research to improve treatment strategies post-ECT.
Article Synopsis
- The study investigates factors influencing medication continuation rates for asenapine sublingual tablets in schizophrenia, highlighting the impact of specific antipsychotics and patient characteristics like age and illness duration.
- Using data from 3,236 cases in Japan, the research identified that higher chlorpromazine doses and longer illness duration (over 25 years) significantly predict better continuation rates for asenapine.
- The findings suggest that predictors for antipsychotic medication continuation vary by drug, emphasizing the need for a tailored approach in treating schizophrenia based on individual patient factors.
Aims: A meta-analysis of short-term studies revealed no significant differences between the doses of asenapine, 10 and 20 mg/day, in the acute treatment of schizophrenia. However, it should be noted that many patients from clinical practice were excluded, and the dose-response to asenapine in a real-world setting is still unclear. Additionally, the dose-response in the maintenance phase is not clear.
View Article and Find Full Text PDFSevoflurane is the most commonly used inhaled anaesthetic in electroconvulsive therapy (ECT). The objective of this study was to provide an up-to-date and comprehensive review on how the use of sevoflurane affects seizure adequacy (seizure duration and postictal suppression index [PSI]) and circulatory dynamics in ECT. We performed a meta-analysis of RCTs that investigated seizure adequacy and circulatory dynamics in patients treated with ECT using sevoflurane (sevoflurane group) and intravenous anaesthetics (non-sevoflurane group).
View Article and Find Full Text PDFArticle Synopsis
- A study investigated the effectiveness and safety of asenapine, a medication for schizophrenia, by categorizing patients based on their psychiatric symptoms using a standard assessment called the Positive and Negative Symptom Scale (PANSS).
- The research involved 529 patients divided into three clusters: those with high positive symptoms (Cluster-P), those with negative symptoms (Cluster-N), and those with generally lower symptoms (Cluster-L).
- Results showed that both 10 and 20 mg/day of asenapine improved PANSS scores in Clusters-N and-L, while only the 20 mg dose was effective in Cluster-P, indicating that patient symptom backgrounds influence treatment efficacy and safety.